Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units

Archives of Surgery

Volumn 132, Issue 11, 1997, Pages 1197-1202

  Gleason, Thomas G ^a,c   May, Addison K ^b   Caparelli, David ^b   Farr, Barry M ^a   Sawyer, Robert G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONFERENCE PAPER; CRITICAL ILLNESS; DRUG SENSITIVITY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MYCOSIS; PRIORITY JOURNAL; SURGICAL PATIENT;

EID: 0030666638     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1997.01430350047008     Document Type: Conference Paper

References (26)

1. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996: a report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1996;24:380-388.
2. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis. 1995;20:1521-1534.
3. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis. 1995;20:1526-1530.
4. Wey SB, Mori M, Pfaller MA, et al. Risk factors of hospital-acquired candidemia: a matched case-control study. Arch Intern Med. 1989;149:2349-2353.
5. Nassoura Z, Ivatury RR, Simon RJ, Jabbour N, Stahl WM. Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy. J Trauma. 1993;35:290-295.
6. Henderson VJ, Hirvela ER. Emerging and reemerging microbial threats. Arch Surg. 1996;131:330-337.
7. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-851.
8. Rex JH, Bennett JE, Sugar AM, et al, for the Candidemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med. 1994;331:1325-1330.
9. Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996;100:617-623.
10. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751-758.
11. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis of intra-abdominal candidiasis in high-risk surgical patients: a double-blind, placebo-controlled study. In: Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 1994.
12. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274-1277.
13. Bailey EM, Hrakovsky DJ, Pybak MJ. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy. 1990;10:146-153.
14. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human inmmunodeficiency virus type 1. Antimicrob Agents Chemother. 1993;37:2449-2453.
15. Bart-Delabesse E, Boiron P, Carlotti A, Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol. 1993;31:2933-2937.
16. Millon L, Manteaux A, Reboux G, et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol. 1994;32:1115-1118.
17. Pfaller M, Jones R, Messer S, et al, and the SCOPE Study Group. Strain variation and antifungal susceptibility among nosocomial blood stream isolates of Candida spp from US hospitals participating in the SCOPE survey. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 1996.
18. Giamarellou H, Antoniadou A. Epidemiology, diagnosis, and therapy of fungal infections in surgery. Infect Control Hosp Epidemiol. 1996;17:558-564.
19. Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of Candida in intraperitoneal infections. Surgery. 1980;88:524-530.
20. Solomkin JS, Flohr AM, Simmons RL. Indications for therapy for fungemia in postoperative patients. Arch Surg. 1982;117:1272-1275.
21. Cornwell EE III, Belzberg H, Berne TV, et al. The pattern of fungal infections in critically ill surgical patients. Am Surg. 1995;61:847-850.
22. Solomkin JS. Timing of treatment for nonneutropenic patients colonized with Candida. Am J Surg. 1996;172:44S-48S.
23. Espinel-Ingroff A, Flynn R. Antifungal activity of the new triazole voriconazole against established, new and emerging yeast pathogens: a comparative study. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 1996.
24. Hoban D, Kabani A, Karlowsky J, et al. Evaluation of in vitro activity of a new echinocandin, LY303366, against systemic isolates of Candida spp and Cryptococcus neoformans. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 1996.
25. Vazquez JA, Boikov D, Lynch ME, Sobel JD. In-vitro antifungal activity of L-743,872 a new pneumocandin, against sensitive and resistant Torulopsis and Candida species. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 1996.
26. Ryder NS, Wagner S, Leitner I. In vitro activity of terbinafine against Candida and other yeasts by NCCLS method. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 1996.